Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: A cost-effectiveness analysis

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 6, 2003, Pages 785-792

  You, J H S ^a   Lee, A C M ^b   Wong, S C Y ^b   Chan, F K L ^c  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b HOSPITAL AUTHORITY   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH CARE; HONG KONG; HUMAN; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMPS; QUALITY-ADJUSTED LIFE YEARS;

EID: 0037445046     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01526.x     Document Type: Article

References (29)

1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 1432-42.
2. Lambert R. Review article, current practice and future perspectives in the management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 11: 651-62.
3. Dent J. Australian clinical trials of omeprazole in the management of reflux oesophagitis. Digestion 1990; 47(Suppl. 1): 69-71.
4. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999; 44(Suppl. 2): S1-16.
5. Lundell L, Backman L, Ekstrom P, et al. Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 1991; 26: 248-56.
6. Website: Hospital Authority, Hong Kong [www.ha.org.hk].
7. Hatlebakk JG, Berstad A, Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis, Aliment Pharmacol Ther 1997; 11: 365-72.
8. Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group. Am J Gastroenterol 1996; 91: 1758-65.
9. Festen HP, Schenk E, Tan G, et al. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. Am J Gastroenterol 1999; 94: 931-6.
10. Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994; 107: 1305-11.
11. Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut 1995; 36: 492-8.
12. Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 1990; 99: 621-8.
13. Kuipers EF, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
14. Sonnenberg FA, Beck RJ. Markov models in medical decision making: a practice guide. Med Decis Making 1993; 13: 322-38.
15. Ethiopia A, Gregor JC, Preiksaitis HG, et al. An evaluation of utility measurement in gastroesophageal reflux disease (GERD). Gastroenterology 1998; 114: G0477.
16. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole vs. ranitidine for prevention of relapse in reflux esophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35: 590-8.
17. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams daily, omeprazole 20 milligrams daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy of symptoms of gastroesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 9065-73.
18. Bate CM, Green JRB, Axon ATR. Omeprazole is more effective than cimetidine for the relief of all grades of gastroesophageal reflux disease-associated heartburn, irrespective of the presence of absence of endoscopic esophagitis. Aliment Pharmacol Ther 1997; 11: 755-63.
19. Kaplan-Nachlis B, Spiegler GE, Zodet MW. Effectiveness and costs of omeprazole vs. ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med 2000; 9: 624-30.
20. Jasen J, Van Oene JC. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. Aliment Pharmacol Ther 1999; 13: 1611-20.
21. Bardhan KD, Hawkey GJ, Long RG, et al. Lansoprazole versus ranitidine for the treatment of reflux esophagitis. Aliment Pharmacol Ther 1995; 9: 145-51.
22. Farley A, Wruble LD, Humphries TJ. Rabeprazole versus rantidine for the treatment of erosive gastroesophageal refux disease: a double-blind randomized clinical trial. Rabeprazole Study Group. Am J Gastroenterol 2000; 95: 1894-9.
23. Escourrou J, Deprez P, Saggioro A, et al. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Aliment Pharmacol Ther 1999; 13: 1481-91.
24. Chang CS, Poon SK, Lien HC, et al. The incidence of reflux esophagitis among the Chinese. Am J Gastroenterol 1997; 92: 668-71.
25. Ho KY, Kang JY, Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am J Gastroenterol 1998; 93: 1816-22.
26. Glamiche JP, Barthelemy P, Hamelin B, et al. Treating the symptoms of gastroesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 765-73.
27. Simon TJ, Roberts WG, Berlin RG, et al. Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis. Clin Ther 1995; 17: 1147-56.
28. Holtmann G, Pbyzer P, Metz M, et al. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2001; 16: 479-85.
29. Kinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.